ArticleFrontiers in medicine2026
Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to characterize the clinicopathological features and therapeutic outcomes of atypical Sweet syndrome (SS) in patients with myelodysplastic syndromes (MDS). Methods: A retrospective analysis was conducted on three patients diagnosed with MDS complicated by atypical SS at Beijing Tsinghua Changgung Hospital between 2019 and 2020. Results: The cohort consisted of a 58-year-old man, a 35-year-old woman, and a 46-year-old man. All patients initially presented with fatigue, and none had received active disease-modifying therapy for MDS prior to the onset of cutaneous manifestations. In all cases, skin lesions originated on the limbs, presenting as painful erythematous plaques accompanied by fever, with histopathological findings consistent with atypical SS. Resolution of SS was achieved through a dual approach combining systemic glucocorticoids and therapy targeting the underlying MDS. Conclusion: Atypical SS is a significant paraneoplastic dermatosis frequently associated with MDS, exhibiting distinctive clinicopathological features. Its heterogeneous presentations necessitate careful evaluation, and effective management requires a dual strategy that addresses both the underlying hematologic disease and the cutaneous inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.